https://orcid.org/0000-0002-3587-298X
Figures & data
Figure 1. Markov model. Analysis: A vs B
ATTR-CM: Transthyretin amyloid cardiomyopathy.The simulation starts with the patients in a hypothetical cohort with ATTR-CM who are not hospitalized for cardiovascular reasons. These patients may or may not be correctly diagnosed. In 1-year periods (simulation cycles) a portion of these patients may continue in the ‘no hospitalization’ state, they may move into the ‘hospitalization’ state due to cardiovascular causes, or they may move into the ‘death’ state. The hospitalized patients may recover, returning to the ‘no hospitalization’ state or they may die.
Table 1. Markov model probabilities
Table 2. Economic model costs (€ 2019)
Table 3. Estimated reduction in mortality with and without diagnosis of ATTR-CM
Figure 2. Life-years gained by a patient diagnosed with ATTR-CM receiving correct symptomatic treatment compared to the undiagnosed patient
represents LYGs after 1, 5, 10, and 15 years, of the correct diagnosis of ATTR-CM (eg. After 1 year, it results in a gain of 0.031 life-years per patient) without taking into account the possibility of starting a specific treatment).
Figure 3. Cardiovascular-related hospitalizations avoided with and without ATTR-CM diagnosis. ATTR-CM: Transthyretin amyloid cardiomyopathy
Table 4. Costs and savings generated per patient diagnosed with ATTR-CM who receives correct symptomatic treatment, compared to the undiagnosed patient. Detailed results